Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$365.3M
145M shares
52-week range
$1.30 – $2.79
85% from low
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
CS
Borrow rate
0.42%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $18.3M | $23.3M | $34.7M | $59.1M | $34.2M | $26.4M | $18.7M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $22.1M |
| Gross profit | $18.3M | $23.3M | $34.7M | $59.1M | $34.2M | $26.4M | −$3.4M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -18.2% |
| R&D | $13.2M | $24.8M | $39.2M | $48.4M | $56.5M | $55.1M | $47.8M |
| Operating income | −$13.0M | −$25.6M | −$35.6M | −$26.6M | −$69.4M | −$74.5M | −$71.5M |
| EBITDA | −$3.3M | −$10.9M | −$18.1M | −$7.8M | −$44.9M | −$47.8M | −$44.5M |
| Net income | −$13.6M | −$17.6M | −$27.0M | −$22.3M | −$50.6M | −$62.0M | −$64.8M |
| Net margin | -74.2% | -75.5% | -77.8% | -37.8% | -148.2% | -235.1% | -347.0% |
| EPS (diluted) | -0.12 | -0.15 | -0.24 | -0.26 | -0.51 | -0.61 | -0.57 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $31M | $-0.41 | $-0.42–$-0.40 | 4 |
| 2027 | $46M | $-0.27 | $-0.37–$-0.15 | 4 |
| 2028 | $65M | $-0.13 | $-0.28–$-0.05 | 4 |
| 2029 | $93M | $0.05 | $0.03–$0.07 | 2 |
Forward consensus · source: Financial Modeling Prep
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
www.omniab.comNo one on the platform currently holds OABI.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 269,600 | $423.3K |
No one on the platform has traded OABI yet.
| $145M |
| — |
| IPHAInnate Pharma S.A. | $1.80 | +0.56% | $169M | — |
| IVVDInvivyd, Inc. | $0.94 | +5.83% | $278M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 9.7× sales vs its 13.0× historical median P/S.
Fair value ≈ $3.44 · price $2.57 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$OABI declared the election of two new Class I directors and the ratification of Ernst & Young as auditor at its 2026 annual meeting.
View on StockTwits ↗$OABI RFK and the NIH are really putting a bullseye on the services.
View on StockTwits ↗$OABI Had nice run from the 1.40 range Need more volume to get it back over2.50 and keep it there. A new signing sales event would be helpful Again major players are holding Recent drop has been on tiny volume
View on StockTwits ↗$OABI Still Holding! Chart going as expected. Updated chart.
View on StockTwits ↗$OABI Brilliant piece that captures OABI's situation perfectly. So if you want to update your understanding of OABI or get to know OABI better, this is essential reading. https://everyticker.com/quote/OABI/analysis/omniab-s-clinical-pipeline-inflection-why-biological-intelligence-creates-a-scalable-royalty-machine-nasdaq-oabi
View on StockTwits ↗$OABI At resistance. I think we push past it this time!
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.